E2F3 and hepatocellular carcinoma: Su et al. reported that E2F3 is a direct target of miR-217 in hepatocellular carcinoma [31]; Zhao and colleagues have reported that KRAS is a downstream target of miR-217 in pancreatic cancer [19].